Drug intelligence / Profile preview

EVQ-222-VIA

Development stage: Unknown
Lead developer: EVŌQ nano

Overview

EVQ-222-VIA is an investigational antiviral drug being developed by EVOQ Bio (also referred to as Evoq Nano, Inc.) for the treatment of COVID-19 and influenza A infections. It is classified as a new molecular entity and is currently in early research or discovery phase, with no defined mechanism of action publicly disclosed. The drug's precise modality, chemical structure, and detailed pharmacological properties have not been published. As of June 2023–March 2025 updates, it remains available for licensing and has not advanced beyond preclinical or discovery stages[1][2].

Beyond the preview

Go deeper on EVQ-222-VIA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVQ-222-VIA.

Explore the full profile